Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy in pretreated pleural mesothelioma
NCT06875076Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in malignant pleural mesothelioma (MPM), sponsored by The First Hospital of Jilin University. Primary endpoint: Objective Response Rate at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT06875076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875076.